NCT04082910

Metoprolol Treatment for Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T Cells

Metoprolol for the Treatment of Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T Cells

• Status: Unknown
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Chinese PLA General Hospital · Academic / Other
• Sex: All
• Age: 16 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The aim of this prospective study is to evaluate the feasibility and efficacy of metoprolol, a beta-1 adrenergic receptor blocker, in the treatment of cytokine release syndrome (CRS) caused by chimeric antigen receptor T (CAR T) cell infusions, its effects on the serum levels of Interleukin-6 (IL-6) and other cytokines.

Conditions

• Solid Tumor
• Hematological Malignancy

Interventions

Type	Name	Description
DRUG	Metoprolol	Metoprolol was given in patients who received CAR T cell therapy for CRS control or CRS precaution.
DRUG	metoprolol, infliximab, etanercept, tocilizumab and/or other agents	During the term of metoprolol use, antibodies (infliximab, etanercept and tocilizumab) and/or other agents were not completely limited to be used under the consideration of clinical requirement for sufficient control of continuously progressed CRS.

Timeline

• Start date: 2019-09-15
• Primary completion: 2022-12-30
• Completion: 2023-12-30
• First posted: 2019-09-10
• Last updated: 2022-04-13

Locations

1 site across 1 country: China